Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature

被引:27
作者
Gkekas, Ioannis [1 ,2 ]
Novotny, Jan [2 ]
Pecen, Ladislav [3 ]
Strigard, Karin [1 ]
Palmqvist, Richard [4 ]
Gunnarsson, Ulf [1 ]
机构
[1] Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden
[2] Sunderby Hosp Lulea, Dept Surg, Lulea, Sweden
[3] Charles Univ Prague, Fac Hosp Pilsen, Prague, Czech Republic
[4] Umea Univ, Dept Med Biosci Pathol, Umea, Sweden
关键词
Colon cancer; microsatellite instability; prognostic factor; predictive factor; meta-analysis; systematic review; COLORECTAL-CANCER; ADJUVANT CHEMOTHERAPY; LYMPHOCYTE RATIO; RECURRENCE; EFFICACY; FLUOROURACIL; RISK; B2;
D O I
10.21873/anticanres.12113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: The prognostic role of microsatellite instability (MSI) in stage II colon cancer patients remains controversial despite the fact that it has been investigated in a number of studies. Hazard ratios differ considerably among these studies. We performed a meta-analysis to define the significance of MSI in this group of patients. Materials and Methods: Studies indexed in PubMed presenting separate data on MSI status and survival outcomes for stage II colon cancer patients have been analyzed using fixed-effect meta-analysis of hazard ratio (HR) according to the method of Peto. Results: Analysis was performed on 19 studies including 5,998 patients. A 47.3% of patients received postoperative chemotherapy and included 52.8% males and 47.2% females. Eight studies included some rectal cancer patients although this cohort was not clearly defined in 3 of these. MSI observed in 20.8% (mean) of patients (median 19.9%). HR for overall survival (OS) of MSI vs. microsatellite stable (MSS) tumors for the entire population: 0.73 (95% confidence interval (CI) = 0.331.65); HR for disease-free survival (DFS): 0.60 (95% CI = 0.271.32). No statistical significant difference was found when studies analyzing MSI with genotyping (MG) and immuno histochemistry (IHC) were compared separately (MG vs. IHC: HR OS 0.45, 95% CI = 0.10-2.05 vs. 0.95, 95% CI = 0.57-1.58; HR DFS 0.51, 95% CI = 0.14-1.85 vs. 0.67, 95% CI = 0.26-1.70). However, numerically MSI determination with genotyping shows significantly lower hazard ratios for both DFS and OS. Separate analysis of studies describing colon cancer patients only showed HR OS 0.72 (95% CI = 0.31-1.71); HR DFS 0.60 (95% CI = 0.27-1.31). Conclusion: No significant relation was found between MSI status and OS or DFS. Routine determination of MSI status to guide postoperative management of stage II colon cancer patients cannot be recommended. New large scale high quality studies are needed to answer this question definitively, since currently analyzed studies vary considerably.
引用
收藏
页码:6563 / 6574
页数:12
相关论文
共 38 条
[1]  
[Anonymous], MOL MED
[2]   Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803 [J].
Bertagnolli, Monica M. ;
Redston, Mark ;
Compton, Carolyn C. ;
Niedzwiecki, Donna ;
Mayer, Robert J. ;
Goldberg, Richard M. ;
Colacchio, Thomas A. ;
Saltz, Leonard B. ;
Warren, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) :3153-3162
[3]   Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature [J].
Bockelman, Camilla ;
Engelmann, Bodil E. ;
Kaprio, Tuomas ;
Hansen, Torben F. ;
Glimelius, Bengt .
ACTA ONCOLOGICA, 2015, 54 (01) :5-16
[4]   CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer [J].
Dalerba, Piero ;
Sahoo, Debashis ;
Paik, Soonmyung ;
Guo, Xiangqian ;
Yothers, Greg ;
Song, Nan ;
Wilcox-Fogel, Nate ;
Forgo, Erna ;
Rajendran, Pradeep S. ;
Miranda, Stephen P. ;
Hisamori, Shigeo ;
Hutchison, Jacqueline ;
Kalisky, Tomer ;
Qian, Dalong ;
Wolmark, Norman ;
Fisher, George A. ;
van de Rijn, Matt ;
Clarke, Michael F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03) :211-222
[5]   Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis [J].
Des Guetz, Gaetan ;
Schischmanoff, Olivier ;
Nicolas, Patrick ;
Perret, Gerard-Yves ;
Morere, Jean-Francois ;
Uzzan, Bernard .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1890-1896
[6]   Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients [J].
Dienstmann, Rodrigo ;
Salazar, Ramon ;
Tabernero, Josep .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (16) :1787-+
[7]   Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision [J].
Donada, Marisa ;
Bonin, Serena ;
Barbazza, Renzo ;
Pettirosso, Daniel ;
Stanta, Giorgio .
BMC GASTROENTEROLOGY, 2013, 13
[8]   Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer [J].
Erlichman, C ;
O'Connell, M ;
Kahn, M ;
Marsoni, S ;
Torri, V ;
Tardio, B ;
Zaniboni, A ;
Pancera, G ;
Martignoni, G ;
Labianca, R ;
Barni, A ;
Seitz, JF ;
Milan, C ;
Bedenne, L ;
Giovannini, M ;
Letreut, YP ;
Skillings, J ;
Shepard, L ;
Zee, B ;
Petrioli, R ;
Francini, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1356-1363
[9]   Adjuvant therapy for completely resected stage II colon cancer [J].
Figueredo, Alvaro ;
Coombes, Megan E. ;
Mukherjee, Som .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (03)
[10]   Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study [J].
Gray, Richard ;
Barnwell, Jennifer ;
McConkey, Christopher ;
Hills, Robert K. ;
Williams, Norman S. ;
Kerr, David J. .
LANCET, 2007, 370 (9604) :2020-2029